GlassScriptPhysician profile
Amy L Berke
NPI 1245598309
$2,470.16
in general payments reported to CMS, 2019-2025
31 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $330 · 2021: $563 · 2022: $178 · 2023: $621 · 2024: $397 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.91 | 2021-2024 | Ubrelvy, Vraylar, Linzess |
| Lilly USA, LLC | $329.70 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $288.90 | 2019-2024 | Wegovy |
| Glaxosmithkline, LLC. | $267.83 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $105.15 | 2020-2021 | |
| Pfizer INC. | $104.82 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.61 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $79.87 | 2019-2024 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $74.11 | 2023 | Rexulti |
| Amarin Pharma, INC. | $68.06 | 2019-2021 | |
| Amgen INC. | $64.39 | 2019-2023 | Repatha |
| Supernus Pharmaceuticals, INC. | $59.13 | 2022-2023 | Qelbree |
| Acella Pharmaceuticals, LLC | $58.53 | 2019-2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $54.17 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $49.99 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.09 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $39.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.45 | 2022 | |
| Esperion Therapeutics, INC. | $33.20 | 2021-2023 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $28.05 | 2021 | |
| Mayne Pharma Commercial LLC | $25.99 | 2023 | |
| Almatica Pharma LLC | $23.08 | 2023 | Loreev Xr |
| Actelion Pharmaceuticals US, INC. | $22.27 | 2024 | Opsumit, Uptravi |
| Idorsia Pharmaceuticals US INC | $19.90 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $18.45 | 2021 | |
| Horizon Therapeutics Plc | $18.21 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.63 | 2021 | |
| Allergan, INC. | $14.69 | 2020 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.63 | 2019 | |
| Corium, LLC | $8.11 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Berke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.